[go: up one dir, main page]

MX2015005574A - Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana. - Google Patents

Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana.

Info

Publication number
MX2015005574A
MX2015005574A MX2015005574A MX2015005574A MX2015005574A MX 2015005574 A MX2015005574 A MX 2015005574A MX 2015005574 A MX2015005574 A MX 2015005574A MX 2015005574 A MX2015005574 A MX 2015005574A MX 2015005574 A MX2015005574 A MX 2015005574A
Authority
MX
Mexico
Prior art keywords
amaranth
treatment
nutraceutical formulation
human behavior
producing
Prior art date
Application number
MX2015005574A
Other languages
English (en)
Inventor
Soriano Garcia Manuel
Original Assignee
Soriano Garcia Manuel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soriano Garcia Manuel filed Critical Soriano Garcia Manuel
Priority to MX2015005574A priority Critical patent/MX2015005574A/es
Priority to PCT/MX2016/000035 priority patent/WO2016175646A1/es
Priority to US15/120,540 priority patent/US20180036359A1/en
Publication of MX2015005574A publication Critical patent/MX2015005574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con un proceso novedoso para la elaboración de una formulación nutracéutica de amaranto, a partir de la semilla entera o completa de amaranto. La formulación nutracéutica de amaranto obtenida a partir de la presente invención posee características únicas para la resolución de problemas de gran relevancia dentro del área prioritaria de la salud pública que afectan significativamente a la población en general, esto es, su uso en el tratamiento de trastornos de la conducta humana como la depresión, el estrés, la ansiedad y en sus casos extremos como son, la esquizofrenia y trastorno de bipolaridad.
MX2015005574A 2015-04-30 2015-04-30 Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana. MX2015005574A (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2015005574A MX2015005574A (es) 2015-04-30 2015-04-30 Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana.
PCT/MX2016/000035 WO2016175646A1 (es) 2015-04-30 2016-04-12 Procedimiento para la obtención de una formulación nutracéutica de amaranto y uso en el tratamiento de trastornos de la conducta humana
US15/120,540 US20180036359A1 (en) 2015-04-30 2016-04-12 Process to obtain a nutraceutical formulation of amaranth and its use in treating human behavior disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2015005574A MX2015005574A (es) 2015-04-30 2015-04-30 Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana.

Publications (1)

Publication Number Publication Date
MX2015005574A true MX2015005574A (es) 2016-10-31

Family

ID=57198752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005574A MX2015005574A (es) 2015-04-30 2015-04-30 Procedimiento para la obtencion de una formulacion nutraceutica de amaranto y uso en el tratamiento de transtornos de la conducta humana.

Country Status (3)

Country Link
US (1) US20180036359A1 (es)
MX (1) MX2015005574A (es)
WO (1) WO2016175646A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006688A (es) * 2004-07-09 2006-01-12 Univ Mexico Nacional Autonoma Producto de amaranto nutritivo, su proceso de elaboracion y su uso en la alimentacion de individuos sanos y/o pacientes con algun tipo de desorden metabolico.
MXPA06013015A (es) * 2006-11-09 2007-02-07 Gastronomia Molecular S A Nuevo proceso de elaboracion y estabilidad de un producto nutritivo de amaranto.
AR064115A1 (es) * 2007-12-04 2009-03-11 Univ Nac Del Litoral Un procedimiento para la obtencion de almidon y concentrado proteico de amaranto y otros granos similares
MX2013011664A (es) * 2013-10-07 2015-04-10 Manuel Soriano García Procedimiento para la obtencion de una formulacion nutraceutica de amaranto con propiedades terapeuticas.

Also Published As

Publication number Publication date
US20180036359A1 (en) 2018-02-08
WO2016175646A1 (es) 2016-11-03

Similar Documents

Publication Publication Date Title
Ballesteros et al. Maintaining older brain functionality: a targeted review
MX367139B (es) Una composicion para el cuidado personal y metodo para elaborarla.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
SG10201903823QA (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
WO2015171918A3 (en) Compositions and uses for treatment thereof
HK1254735A1 (zh) 用於获得免疫刺激性抗原呈递细胞的装置和方法
MX391725B (es) Compuestos y metodos para tratamiento de afecciones neurologicas y cardiovasculares.
UY36868A (es) Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5)
EP3487439A4 (en) COMPUTER ASSISTED DESIGN MATRIX FOR THE MANUFACTURE OF DENTAL DEVICES
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
MX389515B (es) Proceso mejorado para producir fucoxantina y/o polisacáridos de microalgas.
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX389724B (es) Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
PH12017501070B1 (en) Peptides and their use in the treatment of skin
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3352755A4 (en) Novel Compositions and Methods for the Treatment and Prevention of Skin Diseases
CL2016001763A1 (es) Antagonistas selectivos de nr2b
EA201791367A1 (ru) Соединения 2,3,4,5-тетрагидропиридин-6-амин и 3,4-дигидро-2h-пиррол-5-амин - ингибиторы бета-секретазы
MX395492B (es) Usos terapeuticos de l-4 cloroquinurenina.
HK1232289A1 (zh) 分拣蛋白作为针对情感/心境障碍的生物标记的用途
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
UA117779C2 (uk) Піразини як модулятори gpr6
MX2020012065A (es) Compuestos de ciclopentano.